Search

Patients with cutaneous lupus erythematosus (CLE), an autoimmune disease that causes skin inflammation, have a higher risk for atherosclerotic cardiovascular disease (ASCVD), or hardening of the arteries, UT Southwestern Medical Center researchers found.

A computer model of the cellular environment inside the knee developed by UT Southwestern Medical Center researchers sheds light on why women tend to have worse outcomes after knee injuries than men. Their findings, published in Scientific Reports, could facilitate research into new therapies for

An experimental treatment for depression that triggers seizures with magnets significantly improved mental health in patients without some cognitive effects associated with electroconvulsive therapy (ECT), a clinical trial led by UT Southwestern Medical Center researchers showed.

Moderately ill patients hospitalized with COVID-19 have better chances of survival if treated with therapeutic-dose anticoagulation, according to an international study involving 121 sites, including UT Southwestern Medical Center.

Scientists at UTSW have developed a technology that shuttles nanoparticles carrying gene editing and protein replacement tools to the specific tissues where they're needed.

Using genetic engineering, researchers at UT Southwestern and Indiana University have reprogrammed scar-forming cells in mouse spinal cords to create new nerve cells, spurring recovery after spinal cord injury.

Three anticonvulsant drugs commonly used to stop prolonged, potentially deadly seizures each work equally well, according to a national study involving physicians at UT Southwestern.

Surgeons at UT Southwestern have developed and analyzed the benefits of a cutting-edge technique that provides patients with facial paralysis the ability to close their eyes.

A once-daily combination treatment for those with uncontrolled Type 2 diabetes amplifies the treatment’s effects – lowering both weight and the number of hypoglycemic events, and improving quality of life and glucose control ¬– and makes participants more likely to adhere to their medications.

A drug in clinical trials as a treatment for metabolic dysfunction-associated steatotic liver disease (MASLD) works with a one-two punch that shuts down triglyceride production and fatty acid synthesis in liver cells, UT Southwestern Medical Center researchers show in a new study.